Thrombolex, Inc.

Key People

• Marvin Woodall - Co-Founder, Executive Chairman
• Michael J. Cerminaro - Co-Founder, President & CEO
• Tony Litwiller - Chief Commercial Officer
• Brian G. Firth, MD, PhD, FACC, MBA - Ex-Officio Chief Scientific Officer
• John Cerminaro - Chief Financial Officer

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises seasoned professionals with extensive experience in the medical device industry.

The presence of multiple successful MedTech entrepreneurs, including individuals with prior leadership roles in major medical device companies, positions Thrombolex favorably for navigating the complexities of the industry.

Clinical Need

Aspect: Very Strong
Summary: Thrombolex addresses a critical need in the treatment of arterial and venous thromboembolic conditions.

With venous thromboembolism causing up to 100,000 deaths annually in the U.S., there is a significant demand for effective treatments. Thrombolex's BASHIR Endovascular Catheters provide a novel approach to rapidly dissolve blood clots, addressing this urgent clinical need.

Competition

Aspect: Somewhat crowded
Summary: The market for thromboembolic treatment devices includes several established players.

While Thrombolex's products are innovative, the presence of other medical device companies in the thromboembolic treatment space means the company must differentiate itself to capture market share.

Technical Challenge

Aspect: Predictable
Summary: The development of endovascular catheters involves manageable technical challenges.

Thrombolex's catheters utilize a combination of mechanical and pharmacological mechanisms, which, while innovative, are built upon well-understood medical technologies, reducing the risk of unforeseen technical issues.

Patent

Aspect: Strong
Summary: Thrombolex holds multiple patents for its catheter technologies.

The patents protect the unique design and functionality of the BASHIR Endovascular Catheters, preventing competitors from replicating their specific features and supporting the company's market position.

Financing

Aspect: Well-funded
Summary: Thrombolex has secured significant funding to support its operations and growth.

With over $26.8 million raised from investors, including the National Heart, Lung, and Blood Institute, Thrombolex is well-positioned to advance its clinical programs and commercial initiatives.

Regulatory

Aspect: 510k/PMA
Summary: Thrombolex has obtained FDA clearance for multiple devices.

The FDA's 510(k) clearance for the BASHIR Endovascular Catheters allows Thrombolex to market its devices in the U.S., facilitating broader adoption in clinical settings.

Opportunity Rollup

Odds of Success

3.5

Peak Market Share

4.4

Segment CAGR

9.4%

Market Segment

Clot Management Devices

Market Sub Segment

Endovascular Catheters

Key Takeaway

Thrombolex, Inc. is well-positioned in the growing clot management device market, leveraging innovative technology and strong leadership to address a critical clinical need.